IRCT20211118053093N6 IRCT 2023-07-31 Shiraz University of Medical Sciences Levetiracetam in acute manic episode of bipolar disorder Investigating the efficacy of Levetiracetam adjunct to Olanzapine for acute manic episode of bipolar disorder, a Double-blind placebo controlled randomized clinical trial 2023-08-23 anticipated 60 Complete https://irct.ir/trial/71557 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: For this purpose,the table of random numbers and the block randomization method is used. In this method, 60 patients who have conditions will be divided into 30 blocks including 2 patients with Simple randomization. Then one of the 2 patients in the block randomly received or placebo, and 30 patients are assigned to each group, Blinding description: Participants do not know which group they are in. The data analyser does not know which group it is analysing. The number of weeks of drug use is the same, so the patient is blinded to the type of treatment.Data analysis is given only data and does not know what treatment was done for witch group. 2 Bipolar disorder type one. Intervention 1: Control group: In the control group, olanzapine starts with a dose of 5 mg per day and reaches a maximum of 20 mg. Lithium also starts with a dose of 300 mg and reaches a maximum of 900 mg. This group receives placebo along with lithium and olanzapine. Intervention 2: Intervention group: In the intervention group, olanzapine starts with a dose of 5 mg per day and reaches a maximum of 20 mg. Lithium also starts with a dose of 300 mg and reaches a maximum of 900 mg. In addition to lithium and olanzapine, this group receives levetiracetam at a dose of 250 mg per day until the end of the 12th week. No - There is not a plan to make this available Justification or reason for not sharing IPD is There is no further information